Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Cyclerion Therapeutics stock
Learn how to easily invest in Cyclerion Therapeutics stock.
Cyclerion Therapeutics Inc is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclerion Therapeutics employs 32 staff and has a trailing 12-month revenue of around $1.9 million.
How to buy shares in Cyclerion Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CYCN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Cyclerion Therapeutics stock price (NASDAQ: CYCN)Use our graph to track the performance of CYCN stocks over time.
Cyclerion Therapeutics shares at a glance
|Latest market close||$0.84|
|52-week range||$0.46 - $3.37|
|50-day moving average||$0.88|
|200-day moving average||$1.00|
|Wall St. target price||$9.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.24|
Buy Cyclerion Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cyclerion Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cyclerion Therapeutics price performance over time
|1 week (2022-09-22)||-6.59%|
|1 month (2022-08-29)||3.70%|
|3 months (2022-06-29)||52.73%|
|6 months (2022-03-25)||N/A|
|1 year (2021-09-29)||-72.82%|
|2 years (2020-09-29)||-87.81%|
|3 years (2019-09-27)||13.25|
|5 years (2017-09-25)||N/A|
Cyclerion Therapeutics financials
|Revenue TTM||$1.9 million|
|Gross profit TTM||$-29,749,000|
|Return on assets TTM||-58.63%|
|Return on equity TTM||-106.93%|
|Market capitalisation||$36.6 million|
TTM: trailing 12 months
Cyclerion Therapeutics share dividends
We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.
Cyclerion Therapeutics share price volatility
Over the last 12 months, Cyclerion Therapeutics's shares have ranged in value from as little as $0.461 up to $3.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclerion Therapeutics's is 2.215. This would suggest that Cyclerion Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cyclerion Therapeutics overview
Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Frequently asked questionsWhat percentage of Cyclerion Therapeutics is owned by insiders or institutions?
Currently 13.54% of Cyclerion Therapeutics shares are held by insiders and 50.247% by institutions. How many people work for Cyclerion Therapeutics?
Latest data suggests 32 work at Cyclerion Therapeutics. When does the fiscal year end for Cyclerion Therapeutics?
Cyclerion Therapeutics's fiscal year ends in December. Where is Cyclerion Therapeutics based?
Cyclerion Therapeutics's address is: 245 First Street, Cambridge, MA, United States, 02142 What is Cyclerion Therapeutics's ISIN number?
Cyclerion Therapeutics's international securities identification number is: US23255M1053 What is Cyclerion Therapeutics's CUSIP number?
Cyclerion Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23255M105
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert